Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: February 06, 2026
Mochida Pharmaceutical Co., Ltd. [4534.T]
TOKYO, Feb 06 (Pulse News Wire) – Mochida Pharmaceutical Co., Ltd. (4534.T) released its earnings presentation for Q3 FY2026.
Revenue was ¥87.5 billion (+8.4% YoY). Operating profit was ¥7.53 billion (+3.9% YoY).
Ordinary profit was ¥8.35 billion (+9.2% YoY). Net profit was ¥6.34 billion.
Total assets stood at ¥120 billion.
AI-translated content. 🟢 Confidence: High See terms • Original filing
TOKYO, Feb 06 (Pulse News Wire) – Mochida Pharmaceutical Co., Ltd. (4534.T) released its earnings presentation for Q3 FY2026.
5 billion (+8.4% YoY). 53 billion (+3.9% YoY).
35 billion (+9.2% YoY). 34 billion.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.